The area of tumor immunology impacts a variety of clinical and research specialties. The complexity of the malignant diseases’ etiology and pathogenesis requires continuing updates to the providers’ knowledge in order to understand the interventions and innovations which will impact care of patients.
The organizing committees for CITIM Conference 2017 bring together thought leaders from the USA and Europe to provide a comprehensive four-day curriculum related to the treatment, prevention, and diagnostic of malignant diseases diseases, as well as the cellular, molecular and genetic mechanisms of their development and therapy.
Who Should Attend: Physicians, researchers, students and healthcare providers who have an interest in the following areas: Tumor immunobiology, immune regulation (cytokines, growth factors, regulatory T cells, MDSC, dendritic cells, NK, macrophages, neutrophils, mast cells), inflammation and cancer, immunotherapy, vaccines, immunomodeling, immunomics, immune tolerance, immunomonitoring, stem cells, cancer stem cells, biomarkers and related disciplines.
CITIM 2017 Conference will be held in Hotel Ambassador, which is located in the center of a beautiful capital of Czech Republic.
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells for research and in vitro diagnostics. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.